Search clinical trials for: Anlotinib and Penpulimab

Total 273002 results

Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Second Affiliated Hospital...

Unknown

Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Lung, Carcinoma
National Cancer Institute (NCI)
NCIC Clinical Trials Group

Completed

Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer

Endometrial Cancer

Canada
Mayo Clinic
Genentech, Inc.

Completed

Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)

Cholangiocarcinoma | Primary Sclerosing Cholangitis | Chemoprevention | Trisomy 7

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

Gastric Cancer | Esophageal Cancer

United States, Canada
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
Taizhou Hospital

Not yet recruiting

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

Small Cell Lung Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

Metastatic Triple-Negative Breast Cancer

China
National Guard Health Affairs

Suspended

Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer (REALME)

Non-small Cell Lung Cancer Metastatic

Saudi Arabia
Dana-Farber Cancer Institute
Astellas Pharma Inc

Terminated

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Non-Small Cell Lung Cancer | Epidermal Growth Factor Receptor

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Genentech, Inc.

Completed

Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

Non-small Cell Lung Cancer

United States
Ontario Clinical Oncology Group (OCOG)
Roche Pharma AG

Completed

Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL)

Non-small Cell Lung Cancer

Canada
Amsterdam UMC, location VUmc

Completed

Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva®) for Brain Metastases From a Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Brain Metastases

Netherlands
Guangdong Provincial People's Hospital

Unknown

Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Brain Metastases
University of Oklahoma
OSI Pharmaceuticals

Terminated

Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera (OSI-TAR-766)

Polycythemia Vera

United States
M.D. Anderson Cancer Center
United States Department of Defense

Completed

BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC

Lung Cancer

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI); OSI Pharmaceuticals

Completed

Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer

Bladder Cancer

United States
SCRI Development Innovations, LLC
GlaxoSmithKline; OSI Pharmaceuticals

Completed

Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

Non Small Cell Lung Cancer

United States
Eli Lilly and Company

Completed

A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer

Non-Small Cell Lung Cancer | Malignant Solid Tumor

United States
Sun Yat-sen University

Terminated

IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases

Non-Small Cell Lung Carcinoma

China
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Head and Neck Cancer

Canada
Memorial Sloan Kettering Cancer Center

Completed

Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations

Oligometastatic Lung Adenocarcinoma

United States
Hoffmann-La Roche

Completed

An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT) (ELEMENT)

Non-Squamous Non-Small Cell Lung Cancer

Serbia
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Australia, China, Korea, Republic of, Denmark, Germany, Greece, Russian Federation, Hungary, France, Netherlands, New Zealand, Spain, Austria, Slovakia, United Kingdom, Malaysia, Belgium, Lithuania, South Africa, Slovenia, Italy, ... and more
Genentech, Inc.

Completed

A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer | Non-small-cell Lung Carcinoma

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)

Terminated

Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection

Stage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck

Stage IV Ovarian Epithelial Cancer | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma... and other conditions

United States
Peking University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

Gastric Cancer | Adenocarcinoma of Esophagogastric Junction

China
Eisai Inc.

Completed

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Hong Kong, Taiwan, Korea, Republic of, Singapore, Thailand, Malaysia
National Cancer Center, Korea
Hoffmann-La Roche

Active, not recruiting

Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

NSCLC Stage II | NSCLC, Stage IIIA

Korea, Republic of
Pfizer

Completed

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Non-small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Australia, Brazil, Spain, United Kingdom, Singapore, Canada, Hong Kong, Poland, Puerto Rico
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)

Non-Small Cell Lung Cancer

Spain, France, Germany, Switzerland, China, Turkey, Denmark, Egypt, Netherlands
University Hospital, Strasbourg, France

Unknown

Clinical Investigation of Erlotinib as an HCV Entry Inhibitor

Chronic Hepatitis C Infection | HCV Genotype 1b

France
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme

Brain and Central Nervous System Tumors

United States
Samsung Medical Center

Unknown

The Continuation of Erlotinib

Non-small Cell Lung Cancer

Korea, Republic of
University of Michigan Rogel Cancer Center

Withdrawn

A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML

Leukemia, Chronic Myeloid

United States
Novartis Pharmaceuticals

Completed

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia

Netherlands, Italy, France, United Kingdom
Novartis Pharmaceuticals

Completed

Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy

Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Germany, Canada, France, Spain, Italy
Novartis Pharmaceuticals

Completed

A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL

Chronic Myelogenous Leukemia | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)

Japan
Novartis Pharmaceuticals

Completed

Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients (CoRNea)

Chronic Myeloid Leukemia

Germany
Novartis Pharmaceuticals

Completed

Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase ('MACS1252)

CML in Chronic Phase

Germany, Italy, Spain, Belgium, Croatia, Hungary, Netherlands, Austria, France, Greece, Sweden, Switzerland, Bulgaria, Romania, Slovenia, United Kingdom, Lithuania, Slovakia, Denmark, Finland, Norway, Poland, Czech Republic, Portugal, E... and more
Novartis Pharmaceuticals

Completed

Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial

Chronic Myelogenous Leukemia

Poland
Grupo Gallego de Investigaciones Oncologicas

Completed

Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients (XELTA)

Metastatic Adenocarcinoma of the Pancreas

Spain
Qingdao Central Hospital

Recruiting

Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer

Overall Survival

China
Second Affiliated Hospital of Nanchang University

Unknown

Phase I Study of the Combination of Anlotinib With Gefitinib

Non-squamous Non-small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Genentech, Inc.; National Comprehensive Cancer Network

Completed

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Breast Cancer

United States
Sanofi

Completed

Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors

Cancer | Non-small Cell Lung Cancer

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Terminated

A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer

NSCLC

United States
Kyowa Kirin Co., Ltd.

Completed

A Study of ARQ 197 in Combination With Erlotinib

Advanced/Recurrent Non-small-cell Lung Cancer

Japan
Hoffmann-La Roche

Completed

A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

Australia, Hong Kong, Romania, Germany, Russian Federation, United Kingdom, Bulgaria, Malaysia, Latvia, Slovenia, Croatia, Brazil, Italy, Lithuania, India, Mexico, Singapore, Peru, Ukraine

Search clinical trials for: Anlotinib and Penpulimab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations